Sanofi Consumer Healthcare India Q2: PAT up 40% FY26

Key takeaway for investors

Sanofi Consumer Healthcare India Ltd. reported a strong set of quarterly numbers, with multiple data points in public disclosures highlighting year-on-year growth in both revenue and profit. The updates include a quarterly performance table (with figures in crore), a separate Q2 FY26 results note (with figures initially presented in million), and an audited annual performance snapshot for the year ended December 31, 2025.

The stock reaction referenced in the provided data was positive in at least one instance after the results announcement, indicating that investors were tracking the improvement in headline profitability.

Stock price moves cited alongside the results

Two separate price references appear alongside the results-related updates:

• As on 29 May 2026 | 16:01, the price line showed 4,769.80, up 98.90 (2.12%).
• In another update dated Mumbai, November 13, the stock was reported at ₹4,996.20 at 1:30 PM, up 7.25% or 337.90 points.

These snapshots indicate positive demand around the time the company’s quarterly performance was being discussed, although the dates and contexts are presented as separate references.

Quarterly table: quarter ended Jun 25 (crore)

A quarterly results table (figures in crore, except per-share values) for the quarter ended Jun 25 provides a detailed view of revenue, income, expenses, and profitability compared with Mar 26 (QoQ) and Jun 24 (YoY). The table lists Total Revenue at ₹220.90 crore for Jun 25 versus ₹229.20 crore in Mar 26 and ₹164.40 crore in Jun 24.

Profitability lines in the same table show Net Income at ₹60.70 crore in Jun 25 compared with ₹67.80 crore in Mar 26 and ₹29.00 crore in Jun 24. Operating metrics also improved year-on-year, with Operating Income at ₹73.80 crore in Jun 25 versus ₹38.20 crore in Jun 24.

Expenses were higher on a year-on-year basis, including Total Operating Expense of ₹147.10 crore in Jun 25 compared with ₹126.20 crore in Jun 24. The table also reports Selling/General/Admin expenses of ₹32.00 crore in Jun 25 versus ₹24.80 crore in Jun 24.

Summary table: Sanofi Consumer Healthcare India quarterly metrics

Q1CY26 highlights presented in crore (converted from million)

Another disclosure summarised Q1CY26 financial highlights (originally provided in ₹ million). Normalised to crore:

• Revenue from Operations: ₹229.2 crore in Q1CY26, down from ₹251.0 crore in Q4CY25, and up from ₹172.6 crore in Q1CY25.
• Total Income: ₹234.8 crore in Q1CY26, down from ₹255.6 crore in Q4CY25, and up from ₹177.8 crore in Q1CY25.
• Profit Before Tax (PBT): ₹90.7 crore in Q1CY26 versus ₹90.5 crore in Q4CY25 and ₹66.8 crore in Q1CY25.
• Net Profit: ₹67.8 crore in Q1CY26 versus ₹66.5 crore in Q4CY25 and ₹50.0 crore in Q1CY25.
• EPS: ₹29.44 in Q1CY26 versus ₹28.87 in Q4CY25 and ₹21.69 in Q1CY25.

Separately, the dataset also states the company reported revenue of ₹229 crore and net profit of ₹67 crore (figures presented without additional qualifiers in the feed).

Q2 FY26 note: revenue growth and sales mix points

A Q2 FY26 results note states:

• Revenue at ₹233.9 crore, described as 46% growth.
• Domestic sales grew by 20%.
• Export sales grew by more than 10X due to a low base.
• Profit After Tax was up by 40%.

The same combined material also includes another line stating the company reported a 28% YoY increase in Q2 revenue to ₹220.9 crore, and that PAT reached ₹60.7 crore, described as a 21% increase over Q1CY25. These figures align with the quarterly table that lists Total Revenue ₹220.90 crore and Net Income ₹60.70 crore for the referenced quarter.

Additional Q2 details: profit, tax, and nine-month numbers (crore)

One narrative section on Q2 FY26 adds more profitability detail (originally in ₹ million, converted here to crore):

• Operational revenue: ₹233.9 crore versus ₹159.9 crore in Q2 FY25.
• Additional income: ₹3.0 crore.
• Profit before exceptional items and tax: ₹84.1 crore, up from ₹62.4 crore a year earlier.
• Tax liabilities: ₹21.2 crore.
• Net profit: ₹62.9 crore, up from ₹45.0 crore (YoY growth stated as 39.8%).

For the nine months ended September 30, 2025, the same section reports:

• Total income: ₹641.2 crore, up from ₹561.8 crore.
• Profit after tax: ₹173.6 crore.

Some lines around total income and expenses in that paragraph appear truncated in the provided text, so only clearly stated values are included above.

Audit, regulatory filings, and results publication

The company disclosed that its Board meeting held on April 28, 2026 considered and approved unaudited financial results for the quarter ended March 31, 2026. The disclosure references compliance with Regulation 33 of SEBI listing regulations and states the statutory auditors issued a limited review report with an unmodified conclusion for the quarter ended March 31, 2026.

Separately, it is also stated that statutory auditors issued an unqualified audit report on the annual accounts for the year ended December 31, 2025.

Dividend references and shareholder dates

Multiple dividend references are present in the provided material:

• The company declared a dividend of ₹55.00 per share on 17 Apr, 2025.
• AGM-related commentary states the Board recommended a final dividend of ₹75 per equity share compared with ₹55 in the previous year, subject to shareholder approval.
• Another line states the Board considered and recommended a final dividend of ₹48 per equity share (face value ₹10) for the financial year ended December 31, 2025, subject to shareholder approval at the ensuing AGM.

In addition, the text lists:

• Book closure: Saturday, 20 June 2026 to Friday, 26 June 2026 (both days inclusive)
• Dividend payment date: Thursday, 9 July 2026

Annual performance snapshot (year ended Dec 31, 2025)

A financial snapshot (initially provided in ₹ million, converted to crore) reports:

• Revenue: ₹878.4 crore vs ₹724.5 crore (YoY 21%)
• EBITDA: ₹318.8 crore vs ₹243.4 crore (YoY 31%)
• EBITDA margin: 36% vs 34%
• PBT: ₹320.3 crore vs ₹246.8 crore (YoY 30%)
• PAT: ₹240.1 crore vs ₹181.0 crore (YoY 33%)

What to watch next

The feed cites an “upcoming earnings date” as 28 Apr, 2026, and also lists Last Earnings Date: Q4 FY25-26 | 28th, Apr, 2026. Investors tracking future updates can also note the mention that second quarter 2026 results will be reviewed by management during a live audio webcast on July 30, 2026, followed by a Q&A session.

Why these results matter

Across the different disclosures, the common thread is that Sanofi Consumer Healthcare India reported higher year-on-year revenue and profit in the referenced quarters, alongside expense increases and changes in operating metrics. The quarterly table also indicates that profitability measures like operating income and net income were significantly higher versus the prior-year quarter in that dataset.

Dividend-related disclosures are also a key part of the shareholder narrative, though the material contains more than one per-share dividend figure for the same year-end reference. Readers typically track the company’s exchange filings and AGM outcome to confirm the final approved dividend amount.

Conclusion

Sanofi Consumer Healthcare India’s quarterly updates show year-on-year growth in revenue and profit across multiple reported periods, supported by improved operating income in the quarterly table. The next focal points in the provided schedule are shareholder approvals related to dividends and the July 30, 2026 management webcast referenced for second quarter 2026 results.